Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

y affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information about factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2009 Annual Report on Form 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results. Further, the Company undertakes no obligation to update forward-looking statements after the date they are made or to conform the statements to actual results or changes in the Company's expectations.

    Contacts:
    Neurologix
    Marc Panoff, 201-592-6451
    Chief Financial Officer
    marcpanoff@neurologix.net

    Cohn & Wolfe
    Jennifer Paganelli, 212-798-9847
    Jennifer.Paganelli@cohnwolfe.com




    '/>"/>
    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
    2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
    3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
    4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
    5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
    6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
    7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
    8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
    9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
    10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
    (Date:1/22/2015)... SAN DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: ... 31, 2014. Revenue for the quarter was $423.0 million, a ... 2013 (a 14 percent increase on a constant currency basis). ... compared to the quarter ended December 31, 2013. Diluted earnings ...
    (Date:1/22/2015)... Increasing sophistication among enterprise buyers of language services ... 2015, says Moravia CMO, Renato Beninatto ... market research firm Common Sense Advisory, 15 percent of ... and localization needs. "From a language industry perspective, this ...
    Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
    ... Lilly and Company (NYSE: LLY ) announced ... Lilly to access innovation being developed outside the company,s ... independent venture capital firms participating in the Mirror Portfolio ... stage of their development. The first is a molecule ...
    ... 2011 Mylan Inc. (Nasdaq: MYL ) ... launched Voriconazole Tablets, 50 mg and 200 mg, under ... Inc. Mylan was the first company to have filed ... for Voriconazole Tablets and was awarded 180 days of ...
    Cached Medicine Technology:Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines 2Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines 3Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines 4
    (Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
    (Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
    (Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
    (Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
    (Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
    Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
    ... DURHAM, N.C., Sept. 22 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... present at an investor conferences in Zurich on Sept. 30, 2009. , ... Radisson Hotel and is scheduled for 7:00 p.m. The German language presentation ... , , About Oxygen Biotherapeutics, Inc. , ...
    ... WESTFORD, Mass., Sept. 22 Cynosure, Inc. (Nasdaq: ... array of light-based aesthetic treatment systems, today announced that President and ... will present at the third annual Maxim Group Growth Conference in ... will be webcast live over the Internet beginning at 10:00 a.m. ...
    ... transmitted infection rates, researchers say , TUESDAY, Sept. 22 ... wives are more likely to have a sexually transmitted ... new study has found. , The researchers behind ... the risk, noting the widowers might be seduced by ...
    ... SEATTLE, Sept. 22 Milliman, Inc., one of the premier worldwide ... new office in San Juan, Puerto Rico. The consultancy, in concert ... expanding the range and depth of Milliman health-related service offerings. , ... years of experience are ideally suited to meeting client needs in ...
    ... , , MOUNTAIN VIEW, ... devices for clot removal in ischemic stroke patients, today announced the ... catheters are a first-in-class family of devices used to provide distal ... other neurovascular procedures. , , The original ...
    ... , , , ... that it has received certification to the ISO 13485:2003 ... Surgical Adhesives. Receipt of the certification allows Cohera ... approval process for TissuGlu(R), the company,s novel internal surgical ...
    Cached Medicine News:Health News:Cynosure to Present at the Maxim Group Growth Conference 2Health News:Sex With New Partners Raises Widowers' Disease Risk 2Health News:Milliman Announces the Opening of a New Office in San Juan, Puerto Rico 2Health News:Concentric Medical Launches Full Family of DAC(TM) Neurovascular Catheters 2Health News:Cohera Medical Receives ISO 13485 Certification: Company Meets International Standards for Design, Development and Manufacturing of Medical Devices 2
    ... addresses every aspect of patient record-keeping to ... care., The technology platform of Oacis includes ... corethe first commercially viable CDR of its ... quick connectivity and true interoperability among all ...
    ... Medical Record (EMR) system that integrates with Perfect ... ChartMaker is an EMR system that helps ... medical reports, letters, and more. Pen-based, speech ... be installed in a phased implementation to move ...
    Clinician's Desktop provides users the tools needed to coordinate information. Utilizing client/server technology Clinicians Desktop provides users with electronic medical records....
    ... solution for automating the clinical workflow of ... with Clinical Pathways (decision trees) that are ... these Clinical Pathways, documenting a patient encounter ... click" on a wireless pen-tablet computer. Alternatively, ...
    Medicine Products: